News coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.3271479338734 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- 4 Biotech Stocks to Buy for 2018 With Up to 100% Upside Potential (247wallst.com)
- Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : January 1, 2018 (finance.yahoo.com)
- $43.35 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter (americanbankingnews.com)
- Intercept Pharmaceuticals, Inc. (ICPT) – Momentum Stock to Focus – Wall Street Morning (wallstreetmorning.com)
- Intercept Pharmaceuticals, Inc., (NASDAQ: ICPT) – Is The Stock A Good Investment? – Stock Watch (stocksnewstimes.com)
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $56.53 on Thursday. The firm has a market cap of $1,414.50, a price-to-earnings ratio of -3.82 and a beta of -2.05. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 12-month low of $54.98 and a 12-month high of $135.59.
ICPT has been the topic of a number of research analyst reports. Royal Bank of Canada initiated coverage on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 price target on the stock. Laidlaw decreased their price target on shares of Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating on the stock in a report on Friday, September 22nd. Cantor Fitzgerald raised shares of Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price target on the stock in a report on Wednesday, November 1st. Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 target price on the stock. Finally, Wells Fargo & Co reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $141.58.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
What are top analysts saying about Intercept Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals and related companies.